Malignant tumor of colon
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Upon m<sup>6</sup>A methylation-induced upregulation, CBX8 interacts with KMT2b and Pol II to promote LGR5 expression in a noncanonical manner, which contributes to increased cancer stemness and decreased chemosensitivity in CC.
|
31849331 |
2019 |
Malignant tumor of colon
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The human leucine-rich, repeat-containing G protein-coupled receptor 5 (LGR5) is a stem cell marker in numerous adult tissues and is overexpressed in a large number of human carcinoma including colon cancer, breast cancer and oral squamous cell carcinomas (OSCC).
|
30770730 |
2019 |
Malignant tumor of colon
|
0.400 |
Biomarker
|
disease |
BEFREE |
We have previously showed that rapidly cycling Lgr5 stem cells are exquisitely sensitive to extrinsic dietary factors that modulate colon cancer risk.
|
30234553 |
2019 |
Malignant tumor of colon
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Negative LGR5 expression was a significant predictor of peritoneal recurrence in patients with pT4 colon cancer.
|
31000786 |
2019 |
Malignant tumor of colon
|
0.400 |
Biomarker
|
disease |
BEFREE |
The immunohistochemical expression of 3 ABC transporters, including ABC subfamily C member 2 (ABCC2), ABCC3 and ABC subfamily G member 2 (ABCG2), and 3 CSC markers, including sex determining region Y-box 2 (SOX2), leucine-rich repeat-containing G protein-coupled receptor 5 and aldehyde dehydrogenase 1, were determined in 164 CC tissues from patients with stage III CC, who underwent postoperative FOLFOX-4 chemotherapy.
|
31186779 |
2019 |
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We examined the clinicopathological and prognostic significance of LGR5 in CRC TB.
|
31100646 |
2019 |
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Residual tumor cells after chemotherapy in colorectal cancer are LGR5-positive cancer stem cells and their ability to eliminate reactive oxygen species is elevated.
|
31522313 |
2019 |
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
LGR5-positive cancer stem cells may play a critical role in the development of UC-CRC, particularly upon loss of p53 function.
|
31280219 |
2019 |
Malignant tumor of colon
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Leucine-rich repeat-containing G-protein coupled receptor 5 (LGR5) is highly expressed in colorectal tumors and marks colon cancer stem cells that drive tumor growth and metastasis.
|
29718672 |
2018 |
Malignant tumor of colon
|
0.400 |
Biomarker
|
disease |
BEFREE |
Here, we determined whether leucine-rich repeat-containing G protein-coupled receptor 5 (LGR5), known as a stem cell marker for colon cancer and gastric cancer, can serve as a novel GSC marker involved in EMT and a therapeutic target in glioma.
|
30208924 |
2018 |
Malignant tumor of colon
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In this study, we focused on colon cancer with peritoneal metastasis and investigated the association between the expression of CD133, aldehyde dehydrogenase-1 (ALDH1) and leucine-rich repeating G-protein coupled receptor-5 (Lgr5), and disease prognosis.
|
29328371 |
2018 |
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We found that LGR5 expression in the epithelium and stroma was associated with tumor stage, and by integrating functional experiments with LGR5-sorted cell RNA sequencing data from adenoma and normal organoids, we found correlations between LGR5 and CRC-specific genes, including dickkopf WNT signaling pathway inhibitor 4 (<i>DKK4</i>) and SPARC-related modular calcium binding 2 (<i>SMOC2</i>).
|
29467240 |
2018 |
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
RTHF daily gavage suppressed the number and size of CRC in mice and inhibited Lgr5 and Cyclin D1 expressions in tumor tissue.
|
30323621 |
2018 |
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Most importantly, Lgr5+CD44+EpCAM+ cells exhibited more pronounced CSC-like traits than did any other subpopulation, indicating that Lgr5 combined with CD44 and EpCAM can further improve the stem-like traits of CSCs in colorectal cancer.
|
29627827 |
2018 |
Colorectal Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The results of the present study suggest that the nuclear expression of β-catenin and LGR5 and the cytoplasmic expression of GATA6 function together during the development of colorectal carcinoma.
|
29434936 |
2018 |
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
LGR5 has an important role in the EGF-mediated survival and proliferation of early adenoma cells and could have clinical utility in predicting response of CRC patients to EGFR therapy.
|
29149105 |
2018 |
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Taken together, our data suggest a suppressive role of LGR5 in CRC progression.
|
30036518 |
2018 |
Colorectal Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The aim of this study was to assess the clinical relevance of EMT and LGR5 expression in CTCs from CRC patients.
|
29949050 |
2018 |
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Tumor necrosis factor receptor superfamily member 19 (<i>TROY</i>) is involved in the Wnt/β-catenin signaling pathway and interacts with leucine-rich repeat containing G-protein-coupled receptor 5 (LGR5), which is a well-known biomarker of cancer stem cells and a prognostic marker of colorectal cancer (CRC).
|
29556315 |
2018 |
Colorectal Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
This expansion of the LGR5 compartment coincides with maintenance of crypt-like glandular structure (adenomas, and well and moderately differentiated adenocarcinomas), and is reduced in poorly differentiated CRC, where crypt-like glandular architecture is lost, accompanied by reduced epithelial terminal differentiation.
|
28958617 |
2018 |
Colorectal Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We found that HOXA4 and HOXA9 are up-regulated in CRC SCs. siRNA knockdown of HOXA4 and HOXA9 reduced: (i) proliferation and sphere-formation and (ii) gene expression of known SC markers (ALDH1, CD166, LGR5).
|
28464221 |
2018 |
Colorectal Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The study results suggest that heterogeneous expression of Lgr5 may be a risk factor for local invasion and distant metastasis of CRC.
|
30046385 |
2018 |
Colorectal Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
It will further highlight recent studies indicating the plasticity or redundancy of LGR5<sup>+</sup> cells in intestinal cancer progression and assess the overall merit of therapeutically targeting LGR5 in CRC.
|
29844449 |
2018 |
Malignant tumor of colon
|
0.400 |
Biomarker
|
disease |
BEFREE |
LGR5 ablation in colon cancer cells and crypt stem cells resulted in loss of cortical F-actin, reduced cell-cell adhesion, and disrupted localization of adhesion-associated proteins.
|
28739799 |
2017 |
Malignant tumor of colon
|
0.400 |
Biomarker
|
disease |
BEFREE |
Here, using single-cell qPCR analysis, we identified a subset of Lgr5-positive stem cells that emerged during tumorigenesis in a mouse model of colon cancer.
|
28467911 |
2017 |